You want to join a clinical trial. Here’s what to know about the hurdles.

The Gap Between Wanting a Trial and Actually Getting One

Goldlaner.com – A recent online survey polling more than 2,000 adults revealed a striking disconnect in American healthcare: 71% of respondents living with chronic conditions expressed willingness to enroll in a clinical trial if the opportunity were presented. Yet two-thirds of those same patients reported that no physician or clinician had ever brought up the possibility during a routine visit. A separate analysis drawing on 2020 data found that only 9% of adults had ever received an invitation to take part in a study. The numbers underscore a persistent failure in the pipeline between a patient’s desire for cutting-edge care and the system’s ability to deliver it.

Clinical trials remain the indispensable engine behind every new medication, medical device, and therapeutic intervention that reaches the market. Without real-world human data, the Food and Drug Administration cannot grant approval. The difficulty of assembling that data, however, is immense. Estimates suggest that as many as 86% of trials fail to fill their enrollment quotas within the planned study window. Geographic mismatches, out-of-pocket costs, travel burdens, and sheer time demands create a labyrinth of obstacles that deters even motivated patients.

Recruitment Is Only Half the Battle

Getting a volunteer through the front door is merely the first hurdle. Keeping them engaged through weeks or months of follow-up visits, imaging sessions, and questionnaires is an entirely separate challenge. Alan Balch, who serves as executive board chair at the Patient Advocate Foundation — an organization that operates a clinical trial search tool and publishes extensive patient-education resources — frames the problem bluntly:

“Recruitment is one thing — retention is another. Every touchpoint is an opportunity for access and affordability to be a problem.”

Each scheduled visit, each required lab draw, each commute to a distant research site represents another moment where cost, transportation gaps, or caregiving obligations can cause a participant to drop out. For patients managing chronic illness alongside employment and family responsibilities, those friction points accumulate quickly.

What Trials Actually Test

Many people picture a single scenario: one group receives an experimental drug while a control group receives an inert placebo. In practice, the landscape is far broader. Studies may compare different combinations of existing medications, evaluate novel medical devices, assess preventive strategies such as vaccines, examine lifestyle modifications, or refine screening and diagnostic protocols. For individuals facing advanced or terminal illness, enrollment can represent the most promising avenue available for extending life or preserving quality of life.

Mark Fleury, policy principal for emerging science at the American Cancer Society Cancer Action Network, explains the calculus a patient faces when standard options have run their course:

“Cancer is often a fatal disease, and clinical trials offer an opportunity to try something that may or may not be better. If you know the existing standard of care has an average survival of eight months, you want something with a better opportunity.”

Patient advocates also emphasize that even participants assigned to a control arm receive intensive monitoring and the gold standard of care throughout the study period — a level of surveillance many would not otherwise access outside a research setting.

Legislative and Regulatory Moves Underway

The urgency around improving trial participation has gained fresh momentum in recent months. In June, the Department of Health and Human Services unveiled an initiative aimed at streamlining and strengthening clinical research infrastructure across the country. Among its components was a public request for information examining whether current federal regulations — which in some cases discourage sponsors from reimbursing participants for travel, lodging, and related expenses — should be revised.

The following month, roughly 200 patient-advocacy and public-health organizations jointly addressed the Senate sponsors of the Clinical Trial Modernization Act, pressing for its passage. The proposed legislation would permit trial sponsors to cover participants’ medical out-of-pocket costs, including insurance deductibles and copayments, as well as nonmedical expenses such as transportation and childcare. It would also shield up to $2,000 in trial-related financial support from federal taxation, preventing enrollment from jeopardizing eligibility for Medicaid or other income-based assistance programs.

These policy efforts do not yet constitute enacted law, and the regulatory landscape remains in flux. Patients who wish to explore participation today can begin by asking their treating physician directly about open studies, searching the Patient Advocate Foundation’s trial-matching tool, or contacting the sponsoring institution’s research coordinator. Understanding informed consent, potential side-effect profiles, and the time commitment involved before signing on remains essential.

Personal Motivation and the Science of Participation

Not every participant enrolls seeking a cure for themselves. Some contribute because they believe their data will help others. Jim Taylor’s wife, Geri, was diagnosed with Alzheimer’s disease in 2012 and passed away two years ago, more than a decade after that initial diagnosis. The couple subsequently became vocal advocates for people navigating the disease, and Taylor has carried that mission forward. He is currently enrolled in three observational Alzheimer’s studies that employ cognitive assessments and neuroimaging to document how his own brain changes over time relative to cohorts already diagnosed with the condition.

“The reason I’ve done it is so I can explain to people, with some authenticness and experience, what a trial is like.”

His participation illustrates a dimension of trial engagement that pure enrollment statistics miss: the value of lived experience in demystifying the process for others who are weighing whether to step forward. As regulatory and legislative frameworks evolve to lower financial and logistical barriers, the question for millions of Americans with chronic or progressive conditions will remain the same — whether the system can finally meet them where they already are: willing, informed, and ready.